Ozone Therapy for Hepatitis: Historical Use, Evidence, and Current Relevance

Ozone therapy was once explored as a treatment for chronic hepatitis B and C, particularly in the 1990s and early 2000s when effective antiviral options were limited or prohibitively expensive. The therapy primarily used Major Autohemotherapy (MAH) to modulate the immune system and reduce viral load. Today, the landscape has changed dramatically. Direct-acting antivirals (DAAs) cure hepatitis C in over 95% of patients, and effective suppressive therapy exists for hepatitis B. But ozone’s historical role in hepatitis treatment and its potential relevance in specific populations deserves an honest examination.

This article covers how ozone therapy was used for hepatitis, the key clinical studies, why the treatment landscape shifted, and whether ozone has any remaining role for liver disease.

Hepatitis Basics: Why Alternative Treatments Were Sought

Hepatitis B and C are viral infections that cause inflammation and progressive damage to the liver. Left untreated, both can lead to cirrhosis, liver failure, and hepatocellular carcinoma.

Before DAAs arrived in 2013, treating hepatitis C meant 48 weeks of interferon injections and ribavirin. The cure rate was roughly 50%, and the side effects were brutal: flu-like symptoms, depression, anemia, and neutropenia. Many patients could not tolerate the treatment. Some were not eligible at all. This created a genuine gap that alternative therapies attempted to fill.³

How Ozone Was Used for Hepatitis

The primary ozone modality studied for hepatitis was Major Autohemotherapy (MAH). In this procedure, 100-200 mL of the patient’s blood is drawn, mixed with an ozone/oxygen gas mixture at concentrations of 20-40 mcg/mL, and reinfused. The proposed mechanisms include:

• Immune stimulation: Ozone induces cytokine production (interferon-gamma, interleukins) that may enhance the body’s antiviral immune response⁴
• Oxidative inactivation: Reactive oxygen species generated by ozone can damage viral envelopes and proteins, theoretically reducing viral infectivity
• Hepatoprotection: Ozone activates the Nrf2 pathway, upregulating glutathione and other antioxidant enzymes that protect liver cells from oxidative damage⁵
• Improved oxygenation: Enhanced 2,3-DPG levels in red blood cells may improve oxygen delivery to damaged liver tissue

Rectal ozone insufflation was also studied, particularly in Cuba, as a lower-cost alternative to MAH that could be delivered in resource-limited settings.

The Key Studies

Cespedes-Suarez et al. (2015) – Hepatitis B

This Cuban study is the most frequently cited evidence for ozone in hepatitis. Researchers treated 30 chronic hepatitis B patients with rectal ozone insufflation (50 sessions over 12 months). Results showed:¹

• 73% of patients achieved ALT normalization (a marker of liver inflammation)
• 53% showed significant reduction in viral load
• No serious adverse events reported

Limitations: This was an uncontrolled study with no placebo or comparison group. The small sample size and lack of blinding make it impossible to draw definitive conclusions.

Jiao et al. (2008) – Hepatitis B

A Chinese study combined MAH with conventional interferon therapy for chronic hepatitis B. The combination group showed higher rates of HBeAg seroconversion (a marker of immune control over the virus) compared to interferon alone.⁶ However, this study also had methodological limitations and has not been replicated.

“The arrival of direct-acting antivirals in 2013 fundamentally changed the hepatitis treatment landscape. Therapies that were once explored out of necessity became largely irrelevant for hepatitis C overnight.”

Earlier Observational Reports

Several case series from the 1990s and early 2000s, primarily from Cuba, Germany, and Italy, reported improvements in liver enzymes and viral markers in small groups of hepatitis patients treated with ozone. None of these were randomized controlled trials. Most combined ozone with conventional therapies, making it impossible to isolate ozone’s contribution.⁴

Why Ozone Is Largely Irrelevant for Hepatitis C Now

The introduction of sofosbuvir (Sovaldi) in 2013, followed by combination DAAs like Harvoni and Epclusa, transformed hepatitis C from a chronic disease into a curable one. Modern DAA regimens offer:²

• 95-99% sustained virologic response (cure) rates
• 8-12 week treatment courses (compared to 48 weeks of interferon)
• Minimal side effects
• Oral pills only (no injections)
• Pan-genotypic coverage (Epclusa works across all genotypes)

The initial cost barrier ($84,000 for Sovaldi in 2013) has dropped significantly. Generic versions are available in many countries for under $100 per course. In the US, most insurance plans and Medicaid now cover DAAs.

Given these options, pursuing ozone therapy for hepatitis C makes no clinical sense. A treatment with 95%+ cure rates in 8-12 weeks will always outperform an unproven therapy requiring months of sessions.

Does Ozone Still Have a Role for Hepatitis B?

Hepatitis B is a different story. Unlike hepatitis C, there is no cure. Current antiviral medications (tenofovir, entecavir) suppress viral replication but must be taken indefinitely. Functional cure (HBsAg loss) occurs in fewer than 10% of treated patients.⁷

This ongoing unmet need means researchers continue to explore immune-modulating approaches, including therapeutic vaccines, checkpoint inhibitors, and RNA interference therapies. Ozone, as an immune modulator, could theoretically fit into this picture, but several problems remain:

• No randomized controlled trial has studied ozone for hepatitis B
• The Cespedes-Suarez study, while promising, was uncontrolled and small
• Ozone cannot reach integrated HBV DNA (cccDNA) in hepatocyte nuclei, which is the reservoir that maintains chronic infection
• No pharmaceutical company or major research institution is pursuing ozone for hepatitis B

Cost Comparison

Safety Considerations

Ozone therapy is generally well-tolerated when administered correctly. MAH has been used in over 11,000 documented treatments with a low adverse event rate.⁸ However, patients with liver disease face specific risks:

• Advanced cirrhosis may impair the liver’s ability to handle oxidative stress, even at therapeutic ozone doses
• Patients on anticoagulants (common in advanced liver disease) may have increased bleeding risk from venipuncture
• Ozone should never replace proven antiviral therapy. Delaying effective treatment for hepatitis B or C can lead to irreversible liver damage

Bottom Line

Ozone therapy played a minor role in hepatitis treatment during an era when effective antivirals were either unavailable, unaffordable, or intolerable. The Cespedes-Suarez study and others showed some promising signals for hepatitis B, but the evidence base remains thin and methodologically weak. For hepatitis C, the arrival of DAAs made ozone irrelevant. For hepatitis B, the lack of a cure keeps the door open for immune-modulating strategies, but ozone has not proven itself in this role.

Anyone with chronic hepatitis should prioritize proven antiviral therapy. If you are interested in ozone as an adjunct for hepatitis B, discuss it with both your hepatologist and an experienced ozone practitioner, and never use it as a replacement for conventional treatment.

References

1. Cespedes-Suarez J, Martin-Serrano Y, Carballosa-Pena MR, Dager-Carballosa DR. “Response of patients with chronic hepatitis B in one year of treatment with major autohemotherapy.” Journal of Ozone Therapy, 2015;1(1):16-22. DOI: 10.7203/jo3t.1.1.2015.12163
2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. “Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review.” Annals of Internal Medicine, 2017;166(9):637-648. DOI: 10.7326/M16-2575
3. Fried MW, Shiffman ML, Reddy KR, et al. “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.” New England Journal of Medicine, 2002;347(13):975-982. DOI: 10.1056/NEJMoa020047
4. Bocci V. “Ozone as Janus: this controversial gas can be either toxic or medically useful.” Mediators of Inflammation, 2004;13(1):3-11. DOI: 10.1080/09629350410001659397
5. Viebahn-Haensler R, Leon Fernandez OS. “Ozone in medicine. The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases.” International Journal of Molecular Sciences, 2021;22(15):7890. DOI: 10.3390/ijms22157890
6. Jiao XJ, Wang LH, Li N. “Effect of ozone therapy combined with interferon on hepatitis B.” Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2008;18(4):234-236.
7. Lok AS, McMahon BJ, Brown RS, et al. “Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis.” Hepatology, 2016;63(1):284-306. DOI: 10.1002/hep.28280
8. Jacobs MT. “Untersuchung uber Zwischenfalle und typische Komplikationen in der Ozon-Sauerstoff-Therapie.” Ozonachrichten, 1982;1:5-8.

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website